Opisthorchis viverrini infection
Keywords:
liver fluke, cholangiocarcinoma, freshwater snail, cryprinid fish, praziquantel, trematodeAbstract
Opisthorchiasis, caused by consuming infected raw cyprinid freshwater fish or contaminated water with Opisthorchis viverrini, is one of the most important risk factors for cholangiocarcinoma in endemic countries, such as Thailand, Laos, and Cambodia.
It has been stimated that 67.3 million people are at risk of acquiring an O. viverrini infection, and 10 million people are infected.
Nowadays, the gold standard for the diagnosis of liver fluke is the demonstration of eggs in stool samples, nevertheless, there are more diagnosis methods such as immunochromatography, ELISA and PCR test.
The diagnosis of cholangiocarcinoma in most of the patients is in stages III or IV, because most of the patients are asymptomatic or the diagnosis is incidental in a routine health check, that’s the reason why it has a poor prognosis at 5 years.
The standard treatment is the praziquantel. People who don’t tolerate praziquantel could be treated with tribendimidine, with less adverse effects.
References
(Charoensuk, et al., 2019) “Comparison of stool examination techniques to detect Opisthorchis viverrini in low intensity infection,” Acta tropica, 191, pp. 13–16. doi: 10.1016/j.actatropica.2018.12.018.
(Crellen ,et al., 2021) “Towards Evidence-based Control of Opisthorchis viverrini”, Trends in Parasitology 37(5), pp. 370–80. doi:10.1016/j.pt.2020.12.007.
(Fedorova, et al., 2020) “Opisthorchis felineus infection, risks, and morbidity in rural Western Siberia, Russian Federation,” PLoS neglected tropical diseases, 14(6), p. e0008421. doi: 10.1371/journal.pntd.0008421.
(Lee, et al., 2014) “Triple-tissue sampling during endoscopic retrograde cholangiopancreatography increases the overall diagnostic sensitivity for cholangiocarcinoma,” Gut and liver, 8(6), pp. 669–673. doi: 10.5009/gnl13292.
(Loilome, et al., 2021) “Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma.” Expert Opin Investig Drugs 30(9), pp 985–1006. doi:10.1080/13543784.2021.1955102.
(Meister, et al., 2019). “Pooled population pharmacokinetic analysis of tribendimidine for the treatment of Opisthorchis viverrini infections”, Antimicrobial agents and chemotherapy, 63(4), e01391-18. doi:10.1128/AAC.01391-18.
(Pengput, and Schwartz, 2020) “Risk factors for Opisthorchis viverrini infection: A systematic review,” Journal of infection and public health, 13(9), pp. 1265–1273. doi: 10.1016/j.jiph.2020.05.028.
(Petney, et al., 2018) “Taxonomy, ecology and population genetics of Opisthorchis viverrini and its intermediate hosts,” Advances in parasitology. Edited by B. Sripa and P. J. Brindley, 101, pp. 1–39. doi: 10.1016/bs.apar.2018.05.001.
(Phadungsil, et al., 2021) “Efficiency of the stool-PCR test targeting NADH dehydrogenase (nad) subunits for detection of Opisthorchis viverrini eggs,” Journal of tropical medicine, 2021, p. 3957545. doi: 10.1155/2021/3957545.
(Prueksapanich, et al., 2018) “Liver fluke-associated biliary tract cancer,” Gut and liver, 12(3), pp. 236–245. doi: 10.5009/gnl17102.
(Renaldi, K., et al., 2021) “Endoscopic ultrasonography (EUS) compared with magnetic resonance cholangiopancreatography (MRCP) in diagnosing patients with malignancy causing obstructive jaundice,” The Indonesian Journal of Gastroenterology Hepatology and Digestive Endoscopy, 22(1), pp. 29–36. doi: 10.24871/221202129-36.
(Rodpai, et al., 2021) “Rapid assessment of Opisthorchis viverrini IgG antibody in serum: A potential diagnostic biomarker to predict risk of cholangiocarcinoma in regions endemic for opisthorchiasis,” International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases, 116, pp. 80–84. doi: 10.1016/j.ijid.2021.12.347.
(Sadaow, et al., 2019) “Development of an immunochromatographic point-of-care test for serodiagnosis of opisthorchiasis and clonorchiasis,” The American journal of tropical medicine and hygiene, 101(5), pp. 1156–1160. doi: 10.4269/ajtmh.19-0446.
(Sayasone, et al., 2018) “Efficacy and safety of tribendimidine versus praziquantel against Opisthorchis viverrini in Laos: an open-label, randomised, non-inferiority, phase 2 trial,” The Lancet infectious diseases, 18(2), pp. 155–161. doi: 10.1016/S1473-3099(17)30624-2.
(Srinivasamurthy, et al., 2021) ”Chemotherapy of Helminthiasis”, In Introduction to Basics of Pharmacology and Toxicology, pp. 1027-1046. doi:10.1007/978-981-33-6009-9_61.
(Sripa, et al., 2020) “Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient,” Human cell, 33(3), pp. 695–708. doi: 10.1007/s13577-020-00334-w.
(Suwannatrai, et al., 2018) “Epidemiology of Opisthorchis viverrini infection,” Advances in parasitology, 101, pp. 41–67. doi: 10.1016/bs.apar.2018.05.002.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Journal of Microbiology & Health Education
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
